目次

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS
3.1 SURGICAL GOWNS AND DRAPES MARKET OVERVIEW
3.2 SURGICAL GOWNS AND DRAPES MARKET, BY PRODUCT TYPE, 2025 VS. 2030
3.3 SURGICAL GOWNS AND DRAPES MARKET, BY MATERIAL, 2025 VS. 2030
3.4 SURGICAL GOWNS AND DRAPES MARKET, BY STERILITY, 2025 VS. 2030
3.5 SURGICAL GOWNS AND DRAPES MARKET, BY APPLICATION, 2025 VS. 2030
3.6 SURGICAL GOWNS AND DRAPES MARKET, BY END USER, 2025 VS. 2030
3.7 SURGICAL GOWNS AND DRAPES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of healthcare-associated infections
4.2.1.2 Increasing number of surgical procedures
4.2.1.3 Growing focus on infection prevention protocols
4.2.1.4 Expansion of ambulatory surgical centers
4.2.2 RESTRAINTS
4.2.2.1 Reuse of surgical gowns and drapes in developing regions
4.2.2.2 High cost of premium disposable products
4.2.3 OPPORTUNITIES
4.2.3.1 Growth opportunities in emerging countries
4.2.3.2 Adoption of advanced fabric technologies
4.2.4 CHALLENGES
4.2.4.1 Supply chain volatility in raw materials
4.2.4.2 Quality inconsistency among low-cost suppliers
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN SURGICAL GOWNS AND DRAPES MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.6.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.6.3 AVERAGE SELLING PRICE TREND, BY REGION
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 621010)
5.7.2 EXPORT SCENARIO (HS CODE 621010)
5.8 KEY CONFERENCES AND EVENTS, 2025-2026
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.11 CASE STUDY ANALYSIS
5.11.1 CASE STUDY 1: COST BENEFIT ANALYSIS OF SURGICAL GOWN
AND DRAPE SELECTION
5.11.2 CASE STUDY 2: COMPARE IMPACT AND COST-EFFECTIVENESS
LONG FIBER POLYESTER VS. COTTON FABRIC DRAPES
5.11.3 CASE STUDY 3: EVALUATE AND COMPARE PERFORMANCE OF DISPOSABLE VS. REUSABLE MEDICAL GOWNS
5.12 IMPACT OF 2025 US TARIFFS ON SURGICAL GOWNS AND DRAPES MARKET
5.12.1 INTRODUCTION
5.12.2 KEY TARIFF RATES
5.12.3 PRICE IMPACT ANALYSIS
5.12.4 KEY IMPACT ON COUNTRY/REGION
5.12.4.1 North America
5.12.4.2 Europe
5.12.4.3 Asia Pacific
5.12.5 IMPACT ON END-USE INDUSTRIES
5.12.5.1 Hospitals
5.12.5.2 Ambulatory Surgical Centers (ASCs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 SMART TEXTILES (E-TEXTILES)
6.1.2 BIODEGRADABLE AND COMPOSTABLE MATERIALS
6.1.3 ANTIMICROBIAL AND ANTIVIRAL COATINGS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 STERILIZATION TECHNOLOGIES
6.2.2 REUSABLE SURGICAL TEXTILES
6.3 TECHNOLOGY/PRODUCT ROADMAP
6.3.1 SHORT-TERM (2025-2027) | PROCESS IMPROVEMENT & STANDARDIZATION
6.3.2 MID-TERM (2027-2030) | MATERIAL DIVERSIFICATION & SUSTAINABILITY
6.3.3 LONG-TERM (2030-2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT LABWARE
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON SURGICAL GOWNS AND DRAPES MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 BEST PRACTICES IN SURGICAL GOWNS AND DRAPES MARKET
6.7.3 FUTURE OF AI IN SURGICAL GOWNS AND DRAPES MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN SURGICAL GOWNS AND DRAPES
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 SURGICAL GOWNS AND DRAPES MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.2 SURGICAL DRAPES
9.2.1 DISPOSABLE DRAPES
9.2.1.1 Increasing volume of surgeries and growing focus on infection prevention to drive market
9.2.2 REUSABLE DRAPES
9.2.2.1 Durability and sustainability to contribute to growth
9.3 SURGICAL GOWNS
9.3.1 USAGE PATTERN
9.3.1.1 Disposable gowns
9.3.1.1.1 Convenience and single-use nature to foster growth
9.3.1.2 Reusable gowns
9.3.1.2.1 Long-term cost-effectiveness to encourage growth
9.3.2 TYPE
9.3.2.1 Standard performance gowns
9.3.2.1.1 Increasing use of standard performance gowns in
low-risk procedures to favor growth
9.3.2.2 Reinforced gowns
9.3.2.2.1 Rising demand for reinforced gowns to protect healthcare workers during moderate-risk surgical procedures to boost market
9.3.2.3 High-performance gowns
9.3.2.3.1 Lightweight and breathable properties to accelerate growth

10 SURGICAL GOWNS AND DRAPES MARKET: VOLUME ANALYSIS
10.1 INTRODUCTION
10.1.1 US: TOTAL VOLUME OF SURGICAL DRAPES, BY APPLICATION,
2023-2030 (MILLION UNITS)
10.1.2 US: TOTAL VOLUME OF SURGICAL GOWNS, BY APPLICATION,
2023-2030 (MILLION UNITS)

11 SURGICAL GOWNS AND DRAPES MARKET, BY MATERIAL
11.1 INTRODUCTION
11.2 NON-WOVEN MATERIALS
11.2.1 POLYPROPYLENE (PP)
11.2.1.1 Ability to offer varying degrees of fluid resistance, breathability, and comfort to fuel market
11.2.2 POLYETHYLENE (PE)
11.2.2.1 Low-friction surface and ease of manufacturing to spur growth
11.2.3 SPUNBOND-MELTBLOWN-SPUNBOND (SMS)
11.2.3.1 Enhanced durability and resistance to stimulate growth
11.2.4 SPUNLACE MATERIALS
11.2.4.1 Growing adoption of non-wovens in single-use medical barriers to drive market
11.2.5 OTHER NON-WOVEN MATERIALS
11.3 WOVEN FABRICS
11.3.1 COTTON
11.3.1.1 Improved air circulation and compatibility with sensitive skin to boost market
11.3.2 POLYESTER-COTTON BLENDS
11.3.2.1 Higher resistance to wrinkles, abrasion, and shrinkage to aid growth
11.3.3 POLYESTER
11.3.3.1 High level of structural integrity to favor growth
11.3.4 MICROFIBER FABRICS
11.3.4.1 Growing patient volume to drive market
11.3.5 LAMINATED/COATED MATERIALS
11.3.5.1 Enhanced protective qualities and durability to promote growth
11.4 BIODEGRADABLE MATERIALS
11.4.1 RISING GERIATRIC POPULATION AND HIGH INCIDENCE OF
EPILEPSY TO DRIVE MARKET

12 SURGICAL GOWNS AND DRAPES MARKET, BY STERILITY
12.1 INTRODUCTION
12.2 STERILE PRODUCTS
12.2.1 INCREASING FOCUS ON REDUCING RISK OF INFECTIONS TO AID GROWTH
12.3 NON-STERILE PRODUCTS
12.3.1 RISING POPULARITY IN PATIENT WARDS AND EMERGENCY ROOMS TO EXPEDITE GROWTH

13 SURGICAL GOWNS AND DRAPES MARKET, BY APPLICATION
13.1 INTRODUCTION
13.2 CARDIOVASCULAR APPLICATIONS
13.2.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET
13.3 GENERAL SURGERY
13.3.1 INCREASING VOLUME OF GENERAL SURGERIES TO SPUR GROWTH
13.4 GYNECOLOGY
13.4.1 RISING C-SECTION AND HYSTERECTOMY CASES TO BOLSTER GROWTH
13.5 OPHTHALMOLOGY
13.5.1 INCREASING PREVALENCE OF EYE CONDITIONS TO AID GROWTH
13.6 LITHOTOMY & LAPAROSCOPY
13.6.1 QUICK RECOVERY TIMES AND REDUCED COMPLICATIONS
TO FACILITATE GROWTH
13.7 OTHER APPLICATIONS

14 SURGICAL GOWNS AND DRAPES MARKET, BY END USER
14.1 INTRODUCTION
14.2 HOSPITALS
14.2.1 INCREASING NUMBER OF SURGERIES PERFORMED GLOBALLY TO PROMOTE GROWTH
14.3 AMBULATORY SURGICAL CENTERS
14.3.1 RISING FOCUS ON IMPROVED CARE QUALITY AND REDUCED PROCEDURAL COSTS TO BOOST MARKET
14.4 OTHER END USERS

15 SURGICAL GOWNS AND DRAPES MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 US
15.2.1.1 Growing cases of healthcare-associated infections to drive market
15.2.2 CANADA
15.2.2.1 Rising geriatric population to support growth
15.3 EUROPE
15.3.1 GERMANY
15.3.1.1 Growing adoption of hospital disinfection and surveillance systems to boost market
15.3.2 UK
15.3.2.1 Increasing focus on comprehensive, data-driven infection control strategies to fuel market
15.3.3 FRANCE
15.3.3.1 Stringent regulatory guidelines for infection control product commercialization to aid growth
15.3.4 ITALY
15.3.4.1 Increasing establishment of long-term care facilities to boost market
15.3.5 SPAIN
15.3.5.1 Increasing incidence of chronic diseases to spur growth
15.3.6 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 JAPAN
15.4.1.1 Increasing elderly population and healthcare expenditure to drive market
15.4.2 CHINA
15.4.2.1 Rising healthcare spending and increasing prevalence of chronic diseases to drive market
15.4.3 INDIA
15.4.3.1 Extensive patient population to contribute to growth
15.4.4 AUSTRALIA
15.4.4.1 Increasing demand for healthcare services to facilitate growth
15.4.5 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 BRAZIL
15.5.1.1 Robust pharmaceutical and biotechnology industries to drive market
15.5.2 MEXICO
15.5.2.1 Changing demographic trend to encourage growth
15.5.3 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE
16.1 OVERVIEW
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
16.3 REVENUE ANALYSIS, 2022-2024
16.4 MARKET SHARE ANALYSIS, 2024
16.5 BRAND/PRODUCT COMPARISON
16.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
16.6.1 STARS
16.6.2 EMERGING LEADERS
16.6.3 PERVASIVE PLAYERS
16.6.4 PARTICIPANTS
16.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
16.6.5.1 Company footprint
16.6.5.2 Region footprint
16.6.5.3 Product type footprint
16.6.5.4 Application footprint
16.6.5.5 End-user footprint
16.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
16.7.1 PROGRESSIVE COMPANIES
16.7.2 RESPONSIVE COMPANIES
16.7.3 DYNAMIC COMPANIES
16.7.4 STARTING BLOCKS
16.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
16.7.5.1 Detailed list of key startups/SMEs
16.7.5.2 Competitive benchmarking of key startups/SMEs
16.8 COMPANY VALUATION AND FINANCIAL METRICS
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES AND APPROVALS
16.9.2 DEALS
16.9.3 EXPANSIONS
16.9.4 OTHER DEVELOPMENTS

17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 CARDINAL HEALTH
17.1.1.1 Business overview
17.1.1.2 Products offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches and approvals
17.1.1.3.2 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths/Right to win
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses/Competitive threats
17.1.2 MEDLINE INDUSTRIES, LP
17.1.2.1 Business overview
17.1.2.2 Products offered
17.1.2.3 Recent developments
17.1.2.3.1 Deals
17.1.2.3.2 Other developments
17.1.2.4 MnM view
17.1.2.4.1 Key strengths/Right to win
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses/Competitive threats
17.1.3 OWENS & MINOR
17.1.3.1 Business overview
17.1.3.2 Products offered
17.1.3.3 MnM view
17.1.3.3.1 Key strengths/Right to win
17.1.3.3.2 Strategic choices
17.1.3.3.3 Weaknesses/Competitive threats
17.1.4 MCKESSON CORPORATION
17.1.4.1 Business overview
17.1.4.2 Products offered
17.1.4.3 MnM view
17.1.4.3.1 Key strengths/Right to win
17.1.4.3.2 Strategic choices
17.1.4.3.3 Weaknesses/Competitive threats
17.1.5 MÖLNLYCKE AB
17.1.5.1 Business overview
17.1.5.2 Products offered
17.1.5.3 MnM view
17.1.5.3.1 Key strengths/Right to win
17.1.5.3.2 Strategic choices
17.1.5.3.3 Weaknesses/Competitive threats
17.1.6 SOLVENTUM
17.1.6.1 Business overview
17.1.6.2 Products offered
17.1.6.3 Recent developments
17.1.6.3.1 Other developments
17.1.7 PAUL HARTMANN AG
17.1.7.1 Business overview
17.1.7.2 Products offered
17.1.7.3 Recent developments
17.1.7.3.1 Deals
17.1.8 WINNER MEDICAL, CO., LTD.
17.1.8.1 Business overview
17.1.8.2 Products offered
17.1.8.3 Recent developments
17.1.8.3.1 Deals
17.1.9 STERIS
17.1.9.1 Business overview
17.1.9.2 Products offered
17.1.10 ALPHAPROTECH
17.1.10.1 Business overview
17.1.10.2 Products offered
17.1.11 HENRY SCHEIN
17.1.11.1 Business overview
17.1.11.2 Products offered
17.1.12 B.BRAUN SE
17.1.12.1 Business overview
17.1.12.2 Products offered
17.1.13 BOSTON SCIENTIFIC CORPORATION
17.1.13.1 Business overview
17.1.13.2 Products offered
17.2 OTHER PLAYERS
17.2.1 LOHMANN & RAUSCHER GMBH & CO. KG
17.2.2 STANDARD TEXTILE CO., INC.
17.2.3 PLURITEX S.R.L.
17.2.4 MEDICA EUROPE BV
17.2.5 AMARYLLIS HEALTHCARE PVT. LTD.
17.2.6 STERIMED GROUP
17.2.7 GPC MEDICAL
17.2.8 ALLESET
17.2.9 BOEN HEALTHCARE CO., LTD.
17.2.10 PRIONTEX
17.2.11 EURONDA SPA
17.2.12 TIDI PRODUCTS, LLC.

18 RESEARCH METHODOLOGY
18.1 RESEARCH DATA
18.1.1 SECONDARY DATA
18.1.1.1 List of secondary sources
18.1.1.2 Key data from secondary sources
18.1.2 PRIMARY DATA
18.1.2.1 List of primary sources
18.1.2.2 Key data from primary sources
18.1.2.3 Breakdown of primary interviews
18.1.2.4 Key industry insights
18.2 MARKET SIZE ESTIMATION
18.2.1 BOTTOM-UP APPROACH
18.2.1.1 Approach 1: Revenue estimation of key players
18.2.1.2 Approach 2: Study of annual reports and investor presentations
18.2.1.3 Approach 3: Primary interviews
18.2.1.4 Growth forecast
18.2.1.5 CAGR projections
18.2.2 TOP-DOWN APPROACH
18.3 DATA TRIANGULATION
18.4 RESEARCH ASSUMPTIONS
18.4.1 STUDY-RELATED ASSUMPTIONS
18.4.2 PARAMETRIC ASSUMPTIONS
18.4.3 GROWTH RATE ASSUMPTIONS
18.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT
18.5.1 RESEARCH LIMITATIONS
18.5.2 RISK ASSESSMENT

19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS